

# The Journal of Allergy and Clinical Immunology

## High-sensitivity C-reactive protein and allergic endpoints in German adolescents

--Manuscript Draft--

<b>Manuscript Number:</b>	
<b>Article Type:</b>	Letter to the Editor
<b>Section/Category:</b>	Letters to the Editor
<b>Keywords:</b>	high-sensitivity C-reactive protein, eczema, asthma, allergic rhinitis, allergic sensitization, adolescent
<b>Corresponding Author:</b>	Joachim Heinrich, Ph.D. Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat Munich, GERMANY
<b>First Author:</b>	Bo-Yi Yang, PhD
<b>Order of Authors:</b>	Bo-Yi Yang, PhD Iana Markevych, PhD Carla Harris, PhD Marie Standl, PhD Tamara Schikowski, PhD Sibylle Koletzko, Prof Gunda Herberth, PhD Carl-Peter Bauer, Prof Andrea Von Berg, PhD Dietrich Berdel, Prof Guang-Hui Dong, Prof Joachim Heinrich, Ph.D.
<b>Manuscript Region of Origin:</b>	GERMANY
<b>Abstract:</b>	None

October 15<sup>th</sup>, 2018

Prof. Dr. med. Zuhair K. Ballas  
Editor-in-Chief  
The Journal of Allergy and Clinical Immunology

Dear Prof. Ballas,

For your consideration, please find enclosed the manuscript entitled, "**High-sensitivity C-reactive protein and allergic endpoints in German adolescents**" submitted as a research letter to *The Journal of Allergy and Clinical Immunology*.

**Summary of the main contribution of this submitted manuscript:** The associations between hs-CRP levels and allergic endpoints were investigated by only a few studies, and the results were mixed. Most of the previous studies were cross-sectional with a small sample size. In this study, we re-examined this research question using a larger population size (n=1955) and a longitudinal study design. We observed that there was no association between hs-CRP levels and any of the allergic endpoints including allergic sensitization, asthma, eczema, and allergic rhinitis in German adolescents.

The manuscript has been prepared according to the Instructions for Authors of *The Journal of Allergy and Clinical Immunology*. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. All authors have read and approved the final text for submission. The co-authors have no conflicts of interest relevant to this article to disclose.

Thank you very much for consideration of our manuscript.

Sincerely,

Prof. Dr. Joachim Heinrich  
Institute and Clinic for Occupational, Social and Environmental Medicine,  
University Hospital, LMU Munich, Germany  
Ziemssenstrasse 1, 80336 Munich  
Tel: +49 89 440053251  
e-mail: [Joachim.Heinrich@med.uni-muenchen.de](mailto:Joachim.Heinrich@med.uni-muenchen.de)

1 **High-sensitivity C-reactive protein and allergic endpoints in German adolescents**

2 Bo-Yi Yang, PhD<sup>1,2,3,#</sup>; Iana Markevych, PhD<sup>2,3,4,#</sup>; Carla Harris, PhD<sup>3,6</sup>; Marie Standl,  
3 PhD<sup>3</sup>; Tamara Schikowski, PhD<sup>5</sup>; Sibylle Koletzko, Prof<sup>6</sup>; Gunda Herberth, PhD<sup>7</sup>;  
4 Carl-Peter Bauer, Prof<sup>8</sup>; Andrea von Berg, PhD<sup>9</sup>; Dietrich Berdel, Prof<sup>9</sup>; Guang-Hui  
5 Dong, Prof<sup>1</sup>; Joachim Heinrich, Prof<sup>2,3,10,\*</sup>

- 6 1. Guangdong Provincial Engineering Technology Research Center of  
7 Environmental Pollution and Health Risk Assessment, Guangzhou Key  
8 Laboratory of Environmental Pollution and Health Risk Assessment,  
9 Department of Preventive Medicine, School of Public Health, Sun Yat-sen  
10 University, Guangzhou, China.
- 11 2. Institute and Clinic for Occupational, Social and Environmental Medicine,  
12 University Hospital, LMU Munich, Munich, Germany.
- 13 3. Institute of Epidemiology, Helmholtz Zentrum München - German Research  
14 Center for Environmental Health, Neuherberg, Germany.
- 15 4. Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's  
16 Hospital, Munich, Ludwig Maximilian University of Munich, Munich,  
17 Germany.
- 18 5. IUF – Leibniz Research Institute for Environmental Medicine, Düsseldorf,  
19 Germany.
- 20 6. Division of Pediatric Gastroenterology and Hepatology, Dr. von Hauner

- 21 Children's Hospital Munich, Ludwig Maximilian University of Munich,  
22 Germany.
- 23 7. Department of Environmental Immunology/Core Facility Studies, Helmholtz  
24 Centre for Environmental Research – UFZ, Leipzig, Germany.
- 25 8. Department of Pediatrics, Technical University of Munich, Munich, Germany.
- 26 9. Research Institute, Department of Pediatrics, Marien-Hospital Wesel, Wesel,  
27 Germany.
- 28 10. Allergy and Lung Health Unit, Melbourne School of Population and Global  
29 Health, University of Melbourne, Melbourne, Australia.

30 # These authors contributed equally to this article.

31 **\*Corresponding author:**

32

33 Prof. Dr. Joachim Heinrich

34 Institute and Clinic for Occupational, Social and Environmental Medicine, University

35 Hospital, LMU Munich, Germany

36 Ziemssenstrasse 1, 80336 Muenchen

37 Tel: +49 89 440053251

38 e-mail: [joachim.heinrich@med.uni-muenchen.de](mailto:joachim.heinrich@med.uni-muenchen.de)

39 **Funding**

40 The GINIplus study was mainly supported for the first 3 years by the Federal Ministry  
41 for Education, Science, Research and Technology (interventional arm) and Helmholtz  
42 Zentrum Munich (former GSF) (observational arm). The 4 year, 6 year and 10 year  
43 follow-up examinations of the GINIplus study were covered from the respective  
44 budgets of the 5 study centres (Helmholtz Zentrum Munich (former GSF),  
45 Marien-Hospital Wesel, LMU Munich, TU Munich and from 6 years onward also  
46 from IUF—Leibniz Research-Institute for Environmental Medicine) and a grant from  
47 the Federal Ministry for Environment (IUF, FKZ 20462296). The LISA study was  
48 mainly supported by grants from the Federal Ministry for Education, Science,  
49 Research and Technology and in addition from Helmholtz Zentrum Munich (former  
50 GSF), Helmholtz Centre for Environmental Research—UFZ, Leipzig,  
51 Marien-Hospital Wesel, Pediatric Practice, Bad Honnef for the first 2 years. The 4  
52 year, 6 year and 10 year follow-up examinations of the LISA study were covered from  
53 the respective budgets of the involved partners (Helmholtz Zentrum Munich (former  
54 GSF), Helmholtz Centre for Environmental Research—UFZ, Leipzig,  
55 Marien-Hospital Wesel, Pediatric Practice, Bad Honnef, IUF—Leibniz-Research  
56 Institute for Environmental Medicine) and in addition by a grant from the Federal  
57 Ministry for Environment (IUF, FKZ 20462296). The recent 15 year follow-up  
58 examinations of the GINIplus and LISA studies were supported by the Commission of  
59 the European Communities, the 7th Framework Program (MeDALL project) and the  
60 Mead Johnson and Nestlé companies (GINIplus only). B-YY was supported by the

61 National Natural Science Foundation of China (No.81703179). The aforementioned  
62 funding sources had no involvement in the design of the study, collection, analysis  
63 and interpretation of data, writing of the report and decision to submit the article for  
64 publication.

65

#### 66 **Capsule Summary**

67 High-sensitivity C-reactive protein levels are not associated with any of the allergic  
68 endpoints including allergic sensitization, asthma, eczema, and allergic rhinitis in  
69 German adolescents.

70

71 **Keywords:** high-sensitivity C-reactive protein, eczema, asthma, allergic rhinitis,  
72 allergic sensitization, adolescent

73

74 ***To the Editor:***

75 According to the hygiene hypothesis, infections in childhood might be beneficial for  
76 modulating immune tolerance and the subsequent development of allergic disorders.<sup>1</sup>

77 High-sensitivity C-reactive protein (hs-CRP) is a marker of low-grade systemic  
78 inflammation, which has been closely linked to many non-communicable diseases  
79 (NCD).<sup>2</sup> Childhood allergic diseases are considered as the earliest debuting NCD.<sup>2</sup>  
80 Thus, exploring the relationship between hs-CRP and allergies may be valuable not  
81 only for understanding the mechanisms of allergic disease development but also for  
82 early NCD prevention. However, only a handful of epidemiological studies so far  
83 have investigated the relationship between hs-CRP levels and concurrent or later  
84 allergic outcomes in children and adolescents, and the findings were mixed (these  
85 findings are summarized in Table S1).<sup>3-7</sup> Most of these studies adopted a  
86 cross-sectional design<sup>3,4,7</sup> and had a small sample size.<sup>3-6</sup> Therefore, we sought to  
87 re-examine the interrelation between hs-CRP levels and allergic outcomes using a  
88 larger population size and a longitudinal study design.

89 We collected data on hs-CRP levels and six allergic outcomes (i.e., doctor-diagnosed  
90 asthma, eczema, and allergic rhinitis as well as any sensitization, food sensitization,  
91 and aeroallergen sensitization), in 10- and 15-year-old German adolescents from two  
92 German birth cohorts – the “German Infant Study on the influence of Nutrition  
93 Intervention plus environmental and genetic influences on allergy development”  
94 (GINIplus) study and the “Influence of Life-Style Factors on the Development of the  
95 Immune System and Allergies in East and West Germany” (LISA) study. Approval by

96 the local ethics committees and written consent from all families were obtained. For  
97 detailed information on the flow chart of the study participants and study methods,  
98 please see the supplemental materials (Figure S1 and Supplemental methods).

99 Compared to the original GINIplus and LISA participants (n = 9085), samples  
100 included into the current analysis (n=1955) were more likely to be from the GINIplus  
101 intervention or LISA studies, to have atopic parents and parents with high school  
102 education (Table S2). Approximately 41.7% and 13.7% of the study participants had  
103 hs-CRP levels below detection limit at the age of 10 and 15 years, respectively (Table  
104 S3). The prevalence rates of eczema, asthma, and allergic rhinitis were similar at 10  
105 and 15 years. The prevalence of food sensitization was higher at 10 years than in  
106 15-year participants; aeroallergen sensitization showed an opposite trend.

107 We did not detect any significant association between hs-CRP levels and any of the  
108 studied allergic outcomes in the main analysis (Table 1). This finding was consistent  
109 across sensitivity analyses (using different definitions for asthma, eczema, and  
110 allergic rhinitis (Table S4); restricting analyses to participants without infections  
111 during the last 7 days (Table S5); restricting analyses to participants without asthma,  
112 allergic rhinitis or eczema for sensitization outcomes only (Table S6); and including  
113 additional adjustment (Table S7). Similarly, no associations were detected when  
114 associations in 10- and 15-year old adolescents were tested cross-sectionally (data not  
115 shown).

116 In agreement with our findings, Livnat and associates failed to detect any significant



117 association between hs-CRP levels and current asthma in 131 Israeli children aged  
118 6-18 years.<sup>3</sup> In an analysis of 277 Danish children, higher hs-CRP levels at 7 years  
119 was associated with an elevated risk of concurrent allergic rhinitis, asthma, and  
120 sensitization to aeroallergens, food allergens, or any allergen; yet, no associations  
121 were observed between CRP levels at 6 months with later development of allergic  
122 outcomes until 7 years.<sup>6</sup> However, in two analyses by Mustonen and colleagues,  
123 children with elevated hs-CRP levels were at a decreased risk of allergic sensitization,  
124 though not with atopic dermatitis and asthma.<sup>4,5</sup> In addition, a study of 4111 USA  
125 children and adolescents (2-19 years) reported that increased hs-CRP levels were  
126 significantly associated with an elevated risk of atopy and food allergy.<sup>7</sup> The exact  
127 reasons for the mixed findings across the previous studies and our current analysis are  
128 unclear, but may be related to heterogeneity in study design, participants' age at  
129 assessment of hs-CRP and allergic endpoints, study area, or genetic background;  
130 furthermore, chance findings cannot be excluded.

131 Our study had several strengths in terms of the following three aspects: first, while  
132 most of the previous studies collected data on hsCRP or allergic outcomes once, we  
133 utilized repeated measurements on both hs-CRP levels and allergic outcomes; second,  
134 the population size of our study was large and a rich set of covariates was considered,  
135 which reduced a potential for residual confounding; and third, we performed several  
136 sensitivity analyses, in particular, to reduce reverse causality (Table S6) and to  
137 increase power (Table S4), which demonstrated consistency of the effect estimates.

138 However, our study is not without limitation. First, although our analysis was based  
139 on repeatedly collected data from the prospective cohorts and were analyzed using  
140 generalized estimation equation models, we had data on hs-CRP and allergic  
141 outcomes collected around the same time, which may have compromised the ability to  
142 judge the direction of the studied associations. Second, there can be a critical window  
143 (e.g., the first 1000 days of life) for early programming of the immune system,<sup>8</sup> thus  
144 measuring of the hs-CRP levels at 10 and 15 years may be too late to reflect the  
145 low-grade systemic inflammation status of early childhood. This can also help to  
146 explain the null findings observed in our study. Third, study participants were more  
147 likely to be initially recruited (and to further participate in the studies) from the  
148 families with higher socio-economic status compared to the general German  
149 population, which therefore reduces the generalizability of our findings. Fourth, we  
150 used only a single marker (hs-CRP) to reflect systemic inflammation, which is  
151 actually characterized by a range of indicators, such as higher levels of interleukin 6,  
152 interleukin 1B, Tumor Necrosis Factor, and adiponectin.<sup>2</sup> Hs-CRP is an acute-phase  
153 protein that raises quickly after a stimulus up to 48 hours, with the plasma half-life of  
154 19 hours. There might hence be an association with other markers of systemic  
155 inflammation, but not with hs-CRP.

156 In summary, our study suggests that there is no association between hs-CRP levels  
157 and any of the allergic endpoints including allergic sensitization, asthma, eczema, and  
158 allergic rhinitis in German adolescents. More studies are needed to reach a definite  
159 conclusion on whether allergic diseases are inflammatory conditions and which

160 markers, and at which ages, might be most sensitive.

161

## 162 **Acknowledgements**

163 We thank all children and parents for their cooperation, and all technical and  
164 administrative support staff and medical and field work teams. We are also grateful to  
165 all members of the GINIplus and LISA Study Groups.

166

## 167 **Conflict of interests**

168 None.

169

## 170 **Author information**

171 Bo-Yi Yang, PhD, Guangdong Provincial Engineering Technology Research Center of  
172 Environmental Pollution and Health Risk Assessment, Guangzhou Key Laboratory of  
173 Environmental Pollution and Health Risk Assessment, Department of Preventive  
174 Medicine, School of Public Health, Sun Yat-sen University, Guangzhou, China;  
175 Institute and Clinic for Occupational, Social and Environmental Medicine, University  
176 Hospital, LMU Munich, Munich, Germany; Institute of Epidemiology, Helmholtz  
177 Zentrum München - German Research Center for Environmental Health, Neuherberg,  
178 Germany.

179 Iana Markevych, PhD, Institute and Clinic for Occupational, Social and  
180 Environmental Medicine, University Hospital, LMU Munich, Munich, Germany;  
181 Institute of Epidemiology, Helmholtz Zentrum München - German Research Center  
182 for Environmental Health, Neuherberg, Germany; Division of Metabolic and  
183 Nutritional Medicine, Dr. von Hauner Children's Hospital, Munich, Ludwig  
184 Maximilian University of Munich, Munich, Germany.

185 Carla Harris, PhD, Institute of Epidemiology, Helmholtz Zentrum München - German  
186 Research Center for Environmental Health, Neuherberg, Germany; Division of  
187 Paediatric Gastroenterology and Hepatology, Dr. von Hauner Children's Hospital  
188 Munich, Ludwig Maximilian University of Munich, Germany.

189 Marie Standl, PhD, Institute of Epidemiology, Helmholtz Zentrum München -  
190 German Research Center for Environmental Health, Neuherberg, Germany.

191 Tamara Schikowski, PhD, IUF – Leibniz Research Institute for Environmental  
192 Medicine, Düsseldorf, Germany.

193 Sibylle Koletzko, Prof, Division of Pediatric Gastroenterology and Hepatology, Dr.  
194 von Hauner Children's Hospital Munich, Ludwig Maximilian University of Munich,  
195 Germany.

196 Gunda Herberth, PhD, Department of Environmental Immunology/Core Facility  
197 Studies, Helmholtz Centre for Environmental Research – UFZ, Leipzig, Germany

198 Carl-Peter Bauer, Prof, Department of Pediatrics, Technical University of Munich,

199 Munich, Germany.

200 Andrea von Berg, PhD, Research Institute, Department of Pediatrics, Marien-Hospital

201 Wesel, Wesel, Germany.

202 Dietrich Berdel, Prof, Research Institute, Department of Pediatrics, Marien-Hospital

203 Wesel, Wesel, Germany.

204 Guang-Hui Dong, Prof, Guangdong Provincial Engineering Technology Research

205 Center of Environmental Pollution and Health Risk Assessment, Guangzhou Key

206 Laboratory of Environmental Pollution and Health Risk Assessment, Department of

207 Preventive Medicine, School of Public Health, Sun Yat-sen University, Guangzhou,

208 China.

209 Joachim Heinrich, Prof, Institute and Clinic for Occupational, Social and

210 Environmental Medicine, University Hospital, LMU Munich, Munich, Germany;

211 Institute of Epidemiology, Helmholtz Zentrum München - German Research Center

212 for Environmental Health, Neuherberg, Germany; Allergy and Lung Health Unit,

213 Melbourne School of Population and Global Health, University of Melbourne,

214 Melbourne, Australia.

215 **Reference**

- 216 1. Strachan DP. Hay fever, hygiene, and household size. *BMJ* 1989, 299:  
217 1259-1260.
- 218 2. Prescott SL. Early-life environmental determinants of allergic diseases and the  
219 wider pandemic of inflammatory non-communicable diseases. *J Allergy Clin*  
220 *Immunol* 2013, 131: 23-30.
- 221 3. Livnat G, Yoseph RB, Nir V, Hakim F, Yigla M, Bentur L. Evaluation of  
222 high-sensitivity serum CRP levels compared to markers of airway inflammation  
223 and allergy as predictors of methacholine bronchial hyper-responsiveness in  
224 children. *Lung* 2015, 193: 39-45.
- 225 4. Mustonen K, Keski-Nisula L, Vaarala O, Pfefferle PI, Renz H, Riedler J, et al.  
226 Few associations between high-sensitivity C-reactive protein and environmental  
227 factors in 4.5-year-old children. *Pediatr Allergy Immunol* 2012, 23: 522-528.
- 228 5. Mustonen K, Orivuori L, Keski-Nisula L, Hyvarinen A, Pfefferle PI, Riedler J, et  
229 al. Inflammatory response and IgE sensitization at early age. *Pediatr Allergy*  
230 *Immunol* 2013, 24: 395-401.
- 231 6. Chawes BL, Stokholm J, Schoos AMM, Fink NR, Brix S, Bisgaard H. Allergic  
232 sensitization at school age is a systemic low-grade inflammatory disorder. *Allergy*  
233 2017, 72: 1073-1080.
- 234 7. Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz Am, et al.  
235 Association of obesity with IgE levels and allergy symptoms in children and  
236 adolescents: results from the National Health and Nutritional Examination Survey

- 237 2005-2006. *J Allergy Clin Immunol* 2009, 123: 1163-1169.
- 238 8. Panders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal
- 239 microbiota in the development of atopic disorders. *Allergy* 2007, 62: 1223-1236.

240 **Table 1.** Adjusted ORs with 95% CIs for hs-CRP levels and allergic endpoints estimated using generalized estimating equations models\*

Endpoint	No. of observations	hs-CRP category <sup>†</sup>				
		I	II		III	
		Reference	OR (95% CI)	p-value	OR (95% CI)	p-value
Any sensitization	1955	1	0.93 (0.79, 1.09)	0.353	0.99 (0.80, 1.23)	0.929
Food sensitization	1955	1	1.09 (0.87, 1.36)	0.453	1.04 (0.77, 1.41)	0.810
Aeroallergen sensitization	1955	1	0.95 (0.81, 1.11)	0.513	1.03 (0.83, 1.28)	0.762
Asthma	1951	1	0.98 (0.66, 1.46)	0.927	0.77 (0.42, 1.41)	0.400
Eczema	1929	1	1.03 (0.70, 1.51)	0.894	0.85 (0.48, 1.52)	0.592
Allergic rhinitis	1953	1	1.07 (0.82, 1.39)	0.609	1.11 (0.79, 1.58)	0.549

241 Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio.

242 \*All models adjusted for time of follow-up, study area, sex, parental income, body mass index, and child smoking at 15 years.

243 <sup>†</sup>CRP categories at 10 years: CRP-I, below detection limit (<0.02 mg/dl); CRP-II, ≥0.02 mg/dl and <75th sex-specific percentile of those with  
 244 CRP ≥0.02 mg/dl; CRP-III, ≥0.02 mg/dl and ≥75th sex-specific percentile of those with CRP ≥0.02 mg/dl. CRP categories at 15 years: CRP-I,  
 245 below detection limit (<0.016 mg/dl); CRP-II, ≥0.016 mg/dl and <75th sex-specific percentile of those with CRP ≥0.016 mg/dl; CRP-III,  
 246 ≥0.016 mg/dl and ≥75th sex-specific percentile of those with CRP ≥0.016 mg/dl.

247



## 1 **SUPPLEMENTAL METHODS**

### 2 **Study population**

3 The current analysis is based on the data from two ongoing multicenter population-based  
4 prospective birth cohort studies in Germany: the “German Infant Study on the influence of  
5 Nutrition Intervention plus environmental and genetic influences on allergy development”  
6 (GINIplus) study and the “Influence of Life-Style Factors on the Development of the Immune  
7 System and Allergies in East and West Germany” (LISA) study. Detailed information on the  
8 cohorts has been published elsewhere<sup>E1, E2</sup>. Briefly, the GINIplus is a two-armed study  
9 consisting of 5,991 healthy full-term and normal birth weight newborns recruited at selected  
10 maternity wards in Munich and Wesel between 1995 and 1998. The interventional arm  
11 included newborns with family history of allergy. The newborns participated in the  
12 randomized, double-blind controlled intervention trial with hydrolyzed formulas, including  
13 partially hydrolyzed whey, extensively hydrolyzed whey, extensively hydrolyzed casein, or a  
14 conventional cow’s milk. The observational arm included newborns without family history of  
15 allergy, and those whose parents declined participation in the intervention trial. The LISA  
16 cohort is a population-based cohort consisting of 3,094 full-term and normal birth weight  
17 newborns recruited at selected maternity wards in Munich, Leipzig, Wesel, and Bad Honnef  
18 from 1997 to 1999.

19 In both cohorts, parent-completed questionnaires were administered at birth and when  
20 children were 1, 2, 3, 4, 6, 10 and 15 years of age in GINIplus and at 6, 12, 18, and 24 months  
21 and 4, 6, 10 and 15 years of age in LISA. Additionally, blood samples were drawn at 6, 10,  
22 and 15 years from subgroups of the cohorts.

23 Approvals for the two cohorts have been obtained from the local ethics committees (Bavarian  
24 General Medical Council, University of Leipzig, Medical Council of  
25 North-Rhine-Westphalia). All families have signed informed consent.

## 26 **hs-CRP assessment**

27 Serum hs-CRP concentrations at 10- and 15- years were measured using the Roche  
28 (Mannheim, Germany) Tina-quant CRP (latex) high-sensitivity assay. The measured hs-CRP  
29 concentrations had highly right-skewed distribution, as many hs-CRP observations were  
30 below the detection limits. To facilitate data analysis, we categorized hs-CRP levels into three  
31 age- and sex-specific levels<sup>E3</sup>. The hs-CRP categories at 10 years were: CRP-I, below  
32 detection limit ( $<0.02$  mg/dl); CRP-II,  $\geq 0.02$  mg/dl and  $<75$ th sex-specific percentile of those  
33 with CRP  $\geq 0.02$  mg/dl; and CRP-III,  $\geq 0.02$  mg/dl and  $\geq 75$ th sex-specific percentile of those  
34 with CRP  $\geq 0.02$  mg/dl. hs-CRP categories at 15 years old were: CRP-I, below detection limit  
35 ( $<0.016$  mg/dl); CRP-II,  $\geq 0.016$  mg/dl and  $<75$ th sex-specific percentile of those with CRP  
36  $\geq 0.016$  mg/dl; and CRP-III,  $\geq 0.016$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  
37  $\geq 0.016$  mg/dl.

## 38 **Allergic endpoints**

39 For the main analysis, all allergic endpoints were defined based on the information collected  
40 at the 10- and 15-year follow-ups. Doctor-diagnosed eczema and asthma were defined based  
41 on a positive response to the questions “In the past 12 months, was your child diagnosed with  
42 eczema/asthma?” Doctor-diagnosed allergic rhinitis was defined based on a positive response  
43 to one of the following two questions: “In the past 12 months, has your child been diagnosed  
44 with hay fever/allergic rhinitis?”

45 Specific IgE against common allergens was assessed in serum collected at the 10- and 15-year  
46 follow-ups using the standardized CAP-RAST FEIA method (ThermoFischer, Freiburg,  
47 Germany). Allergic sensitization to aeroallergens (SX1: house dust mites, cats, dogs, mold,  
48 birch, rye, mugwort and timothy grass), as well as allergic sensitization to food allergens  
49 (FX5: milk, peanut, eggs, soya, cod and wheat flour), was defined as a specific IgE value

50 above 0.35 kU/L against SX1 and FX5 allergens, respectively. Any sensitization was defined  
51 as an allergic sensitization to either aero- or food allergens.

52 For a sensitivity analysis, eczema, asthma and allergic rhinitis were defined based on the  
53 information collected from birth (eczema) or from 3 years onwards (asthma and allergic  
54 rhinitis)<sup>E4</sup>. This was done due to the difficulty of accurate diagnosis of asthma and allergic  
55 rhinitis at very young ages<sup>E5</sup>. Each of these three outcomes was defined as satisfying two out  
56 three following criteria: (1) doctor diagnosis ever, (2) having symptoms in the last 12 months,  
57 and (3) taking medication in the last 12 months.

## 58 **Covariates**

59 The following potentially important covariates were considered for this analysis: sex, study  
60 (GINIplus intervention vs. GINIplus observation vs. LISA), study area (Munich vs. Leipzig  
61 vs. Wesel vs. Bad Honnef), time-specific net equivalent household income (defined as time-  
62 and city-specific income tertiles due to large income difference among cities, time-specific  
63 body mass index (BMI, kg/m<sup>2</sup>), time-specific exposure to tobacco smoke at home in the last  
64 12 months, child's smoking status (as ever smoking) at 15 years, parental education level  
65 (based on highest parental level of education: both parents with less than 10 years of school  
66 (low), at least one parent with 10 years of school (medium), at least one parent with more than  
67 10 years of school (high), classified according to the German education system), and parental  
68 history of allergic diseases (self-report of doctor diagnosis of asthma, allergic rhinitis or  
69 eczema, collected at birth). Missing values in income variables, which were many, were coded  
70 as a separate category.

## 71 **Statistical analysis**

72 We used generalized estimation equation (GEE) models<sup>E6</sup> with log link and exchangeable  
73 correlation structure to assess the associations between hs-CRP levels and allergic endpoints

74 at 10 and 15 years of age because of the longitudinal design of the current study (i.e.,  
75 exposure and outcomes). Thus, the results are presented as odds ratios (OR) with  
76 corresponding 95% confidence intervals (CIs).


77 We adjusted main models for time of follow-up and the covariates, which were associated  
78 with hs-CRP, as well as at least one of the outcome endpoints. Thus, the main models were  
79 adjusted for sex, study area, net equivalent household income, BMI, and child's smoking at 15  
80 years. We also performed several sensitivity analyses. First, we re-ran the models for eczema,  
81 asthma, and allergic rhinitis using alternative definitions (Table S4). This was done to achieve  
82 larger power to detect possible associations, as prevalence of asthma and eczema based  
83 exclusively on doctor diagnosis in the past 12 months were low (Table S3). Second,  
84 participants who had infections during the last 7 days prior to blood collection at 10 or 15  
85 years, or participants with such information missing were excluded from the analytic sample,  
86 as their CRP levels could have been affected (Table S5). Third, participants who had asthma,  
87 eczema, and allergic rhinitis (alternative definitions), or participants with such information  
88 missing, were excluded from the analysis with sensitization outcomes (Table S6). Fourth,  
89 models were additionally adjusted for the covariates, which were associated with either  
90 hs-CRP, or at least one of the allergic endpoints – study, parental education level and parental  
91 history of allergic diseases (Table S7). Finally, we explored cross-sectional associations in 10-  
92 and 15- year old participants separately by running logistic (instead of GEE) models.

93 We performed all the statistical analyses using the program R, version 3.5.0 (Vienna,  
94 Austria).<sup>E7</sup> GEE models were fitted by the *geeglm* function from the *geepack* package.<sup>E8</sup>

95

96 **References**

- 97 E1. von Berg A, Krämer U, Link E, et al. Impact of early feeding on childhood eczema:  
98 development after nutritional intervention compared with the natural course - the  
99 GINIplus study up to the age of 6 years. *Clin Exp Allergy* 2010;40(4):627-636.
- 100 E2. Zutavern A, Brockow I, Schaaf B, Bolte G, von Berg A, Diez U, Borte M, Herbarth O,  
101 Wichmann HE, Heinrich J; LISA Study Group. Timing of solid food introduction in  
102 relation to atopic dermatitis and atopic sensitization: results from a prospective birth  
103 cohort study. *Pediatrics* 2006;117:401–411.
- 104 E3. Harris C, Demmelmair H, von Berg A, et al. Associations between fatty acids and  
105 low-grade inflammation in children from the LISApplus birth cohort study. *Eur J Clin*  
106 *Nutr* 2017, 71: 1303-1311.
- 107 E4. Lodrup Carlsen KC, Haland G, et al. Asthma in every fifth child in Oslo, Norway: a  
108 10-year follow up of a birth cohort study. *Allergy*. 2006;61:454–60.
- 109 E5. Markevych I, Baumbach C, Standl M, et al. Early life travelling does not increase risk of  
110 atopic outcomes until 15 years: results from GINIplus and LISApplus. *Clin Exp Allergy*  
111 2017, 47: 395-400.
- 112 E6. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models.  
113 *Biometrika* 1986, 73: 13-22.
- 114 E7. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R  
115 Foundation for Statistical Computing: 2012. Available at: <http://www.R-project.org/>.
- 116 E8. Højsgaard S, Halekoh U, Yan J. The R Package geepack for generalized estimation  
117 equations. *J Stat Software* 2006, 15: 1-11.
- 118



119

120 **Figure S1. Flow chart of study participants.** \*Main covariates included study area, sex,  
 121 BMI and child's smoking at 15 years. Missing values in income variables were coded as a  
 122 separate category.

**Table S1** Prior studies on hs-CRP levels and childhood allergic endpoints

<b>Authors (year)</b>	<b>Country</b>	<b>Study design</b>	<b>Age of hs-CRP and outcomes assessment</b>	<b>Sample size</b>	<b>Main findings</b>
Visness et al. (2009)	United States	Cross-sectional	2-19 years	4111	Elevated CRP levels were associated with a significant increased risk of food allergy (OR = 1.25, 95% CI = 1.01-1.55), and a borderline significant increased risk of atopy (OR = 1.22, 95% CI = 1.00-1.49).
Mustonen et al. 2012	Finland, Germany, Austria, France, Switzerland	Cross-sectional analysis in birth cohort study	4.5 years	653	Children with CRP levels lower than the 75 <sup>th</sup> percentile had a lower risk of sensitization to inhaled allergens and seasonal allergens compared to those with CRP levels below the detection limit. However, no significant further decrease in risk of different sensitizations was observed in those with CRP levels higher than 75 <sup>th</sup> percentile. In addition, no association was detected when CRP was used as a continuous variable.
Mustonen et al. (2013)	Finland, Germany, Austria, France, Switzerland	Longitudinal	1 year and 4.5 years	636	Increased CRP levels at the age of 1 year were associated with a decreased risk of allergic sensitization at the age of 4.5 years only in non-sensitized children at 1 year old. However, no association was observed for the overall population.
Livnat et al. (2015)	Israel	Cross-sectional	6-18 years	131	No significant association was observed between CRP levels and current asthma in children aged 6-18 years.

---

Chawes et al. (2017)	Denmark Longitudinal (7 6 months and 7 277 follow-up years) years	Elevated CRP levels at 7 years were associated with a concurrent (6 years) higher risk of any sensitization, aeroallergen sensitization, food sensitization, asymptomatic sensitization, allergic rhinitis, and asthma. However, CRP levels at 6 months were not associated with later development of allergy endpoints in longitudinal analyses.
----------------------	--	---

---

Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio.



**Table S2** Baseline characteristics of the originally recruited participants and the participants from the analytic sample, n (%)

<b>Variable</b>	<b>Recruited participants</b>	<b>Analytic sample</b>	<b>p-value*</b>
Study			<0.0001
GINIplus observation	3739 (41.2)	582 (30)	
GINIplus intervention <sup>†</sup>	2252 (24.8)	652 (33)	
LISA	3094 (34.1)	721 (37)	
Area			<0.0001
Munich	4413 (48.6)	1060 (54)	
Leipzig	976 (10.7)	205 (11)	
Bad Honnef	306 (3.4)	91 (4.7)	
Wesel	3390 (37.3)	599 (31)	
Sex			0.848
Female	4349 (47.9)	957 (49)	
Male	4575 (50.4)	998 (51)	
Missing	161 (1.8)	0 (0.0)	
Parental education <sup>§</sup>			<0.0001
Low (<10 years)	969 (10.7)	93 (4.8)	
Medium (10 years)	2656 (29.2)	500 (26)	
High (>10 years)	5379 (59.2)	1356 (69)	
Missing	81 (0.9)	6 (0.3)	
Parental history of allergic diseases <sup>¶</sup>			<0.0001
No	4081 (44.9)	738 (38)	
Yes	4841 (53.3)	1199 (61)	
Missing	163 (1.8)	18 (0.9)	

Abbreviations: GINIplus, the German Infant Study on the influence of Nutrition Intervention plus environmental and genetic influences on allergy; LISApplus, the Immune System and the development of Allergies in childhood study.

\*p-value from Chi-Square test.

<sup>†</sup>Group that participated in the intervention trial with hypoallergenic formulae.

<sup>§</sup>Definition based on highest parental level of education: both parents with less than 10 years of school (low), at least one parent with 10 years of school (medium), at least one parent with more than 10 years of school (high), classified according to the German education system.

<sup>¶</sup>Definition based on either of the parents having ever doctor-diagnosed asthma, allergic

rhinitis or eczema

**Table S3** Characteristics of the study participants (n=1955)

Variable	Baseline		10 years		15 years	
	n/N or mean	% or SD	n/N or mean	% or SD	n/N or mean	% or SD
<i>Covariates</i>						
Area						
Munich	1060/1955	54.2	-	-	-	-
Leipzig	205/1955	10.5	-	-	-	-
Bad Honnef	91/1955	4.7	-	-	-	-
Wesel	599/1955	30.6	-	-	-	-
Study						
GINIplus observation	582/1955	29.8	-	-	-	-
GINIplus intervention*	652/1955	33.4	-	-	-	-
LISA	721/1955	36.9	-	-	-	-
Sex - female	957/1955	49.0	-	-	-	-
Parental history of allergic diseases - yes	1199/1937	61.9	-	-	-	-
Parental education <sup>†</sup>						
Low (<10 years)	93/1949	4.8	-	-	-	-
Medium (10 years)	500/1949	25.7	-	-	-	-
High (>10 years)	1356/1949	69.6	-	-	-	-
Child smoking - yes	-	-	-	-	142/1955	7.3
Household income						

Low	-	-	563/1955	28.8	545/1955	27.9
Medium	-	-	659/1955	33.7	587/1955	30.0
High	-	-	583/1955	29.8	585/1955	29.9
Missing	-	-	150/1955	7.7	238/1955	12.2
BMI (kg/m <sup>2</sup> ) <sup>§</sup>	-	-	17.33	2.43	20.79	3.18
Infections last 7 days - yes	-	-	437/1898	23.0	425/1955	21.7
<b><i>hs-CRP</i></b> <sup>¶</sup>						
I	-	-	815/1955	41.7	267/1955	13.7
II	-	-	884/1955	45.2	1260/1955	64.5
III	-	-	256/1955	13.1	428/1955	21.9
<b>Outcomes</b>						
Any sensitization - yes	-	-	854/1955	43.7	943/1955	48.2
Food sensitization - yes	-	-	359/1955	18.4	220/1955	11.3
Aeroallergen sensitization - yes	-	-	760/1955	38.9	916/1955	46.9
Asthma - yes <sup>£</sup>	-	-	72/1904	3.8	75/1911	3.9
Asthma using alternative definitions - yes <sup>⊖</sup>	-	-	118/1923	6.1	131/1909	6.9
Eczema - yes <sup>£</sup>	-	-	89/1900	4.7	61/1896	3.2
Eczema using alternative definitions - yes <sup>⊖</sup>	-	-	215/1924	11.2	176/1907	9.2
Allergic rhinitis - yes <sup>£</sup>	-	-	199/1882	10.6	211/1884	11.2
Allergic rhinitis using alternative definitions - yes <sup>⊖</sup>	-	-	224/1881	11.9	351/1888	18.6

Abbreviations: BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; GINIplus, the German Infant Study on the influence of Nutrition Intervention plus environmental and genetic influences on allergy; LISA, the Immune System and the development of Allergies in childhood study.

\*Group that participated in an intervention trial with hypoallergenic formulae.

†Definition based on highest parental level of education: both parents with less than 10 years of school (low), at least one parent with 10 years of school (medium), at least one parent with more than 10 years of school (high), classified according to the German education system.

§Mean ± Standard Deviation

¶CRP categories at 10 years: CRP-I, below detection limit (<0.02 mg/dl); CRP-II,  $\geq 0.02$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl; CRP-III,  $\geq 0.02$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl. CRP categories at 15 years: CRP-I, below detection limit (<0.016 mg/dl); CRP-II,  $\geq 0.016$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl; CRP-III,  $\geq 0.016$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl.

‡Defined as a parental report of doctor diagnosis during the last 12 months.

°The definitions are based on satisfying two out of three criteria: (1) ever doctor diagnosis from 1 (eczema) or 3 years onwards (asthma and allergic rhinitis), (2) medication use during last 12 months, and (3) allergic diseases symptoms during last 12 months.

**Table S4** Adjusted ORs with 95% CIs\* for hs-CRP levels and alternative definitions of eczema, asthma, and allergic rhinitis † estimated using generalized estimation equation models

Outcome	No. of observations	hs-CRP category <sup>§</sup>				
		I Reference	II OR (95% CI)	p-value	III OR (95% CI)	p-value
Asthma	1953	1	1.05 (0.76, 1.45)	0.778	0.84 (0.54, 1.33)	0.465
Eczema	1951	1	1.00 (0.77, 1.30)	0.982	0.86 (0.60, 1.24)	0.428
Allergic rhinitis	1948	1	0.92 (0.73, 1.17)	0.506	0.84 (0.61, 1.15)	0.275

Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio.

\*All models adjusted for time of follow-up, study area, sex, parental income, body mass index, and child's smoking at 15 years.

†The definitions are based on satisfying two out of three criteria: (1) ever doctor diagnosis from 1 (eczema) or 3 years onwards (asthma and allergic rhinitis), (2) medication use during last 12 months, and (3) allergic diseases symptoms during last 12 months.

§CRP categories at 10 years: CRP-I, below detection limit (<0.02 mg/dl); CRP-II,  $\geq 0.02$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl; CRP-III,  $\geq 0.02$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl. CRP categories at 15 years: CRP-I, below detection limit (<0.016 mg/dl); CRP-II,  $\geq 0.016$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl; CRP-III,  $\geq 0.016$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl.

**Table S5** Adjusted ORs with 95% CIs\* for hs-CRP and allergic outcomes in participants without infections during last 7 days estimated using generalized estimation equation models

Outcome	No. of observations	hs-CRP category <sup>†</sup>				
		I Reference	II OR (95% CI)	p-value	III OR (95% CI)	p-value
Any sensitization	1857	1	0.90 (0.75, 1.08)	0.250	0.99 (0.77, 1.28)	0.958
Food sensitization	1857	1	0.96 (0.75, 1.24)	0.777	0.95 (0.66, 1.35)	0.770
Aeroallergen sensitization	1857	1	0.94 (0.79, 1.13)	0.534	1.07 (0.83, 1.38)	0.594
Asthma	1836	1	1.01 (0.65, 1.56)	0.982	0.82 (0.41, 1.64)	0.583
Eczema	1821	1	1.18 (0.76, 1.84)	0.465	0.86 (0.44, 1.68)	0.653
Allergic rhinitis	1824	1	1.00 (0.74, 1.34)	0.994	1.26 (0.85, 1.87)	0.251

Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio.

\*All models adjusted for time of follow-up, study area, sex, parental income, body mass index, and child's smoking at 15 years.

<sup>†</sup>CRP categories at 10 years: CRP-I, below detection limit (<0.02 mg/dl); CRP-II,  $\geq 0.02$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl; CRP-III,  $\geq 0.02$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl. CRP categories at 15 years: CRP-I, below detection limit (<0.016 mg/dl); CRP-II,  $\geq 0.016$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl; CRP-III,  $\geq 0.016$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl.

**Table S6** Adjusted ORs with 95% CIs\* for hs-CRP and sensitization outcomes in participants without allergic manifestation† estimated using generalized estimation equation models

Outcome	No. of observations	hs-CRP category <sup>§</sup>				
		I Reference	II OR (95% CI)	p-value	III OR (95% CI)	p-value
Any sensitization	1571	1	0.98 (0.80, 1.20)	0.858	1.13 (0.87, 1.48)	0.354
Food sensitization	1571	1	1.10 (0.81, 1.49)	0.544	0.97 (0.64, 1.48)	0.884
Aeroallergen sensitization	1571	1	1.01 (0.82, 1.24)	0.922	1.20 (0.92, 1.58)	0.181

Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio.

\*Adjusted for time of follow-up, study area, sex, parental income, body mass index, and child smoking at 15 years.

†Allergic manifestation is defined as no asthma, allergic rhinitis, or eczema using two out of the following three criteria: (1) ever doctor diagnosis from 1 (eczema) or 3 years onwards (asthma and allergic rhinitis), (2) medication use during last 12 months, and (3) allergic diseases symptoms during last 12 months.

§CRP categories at 10 years: CRP-I, below detection limit (<0.02 mg/dl); CRP-II,  $\geq 0.02$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl; CRP-III,  $\geq 0.02$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl. CRP categories at 15 years: CRP-I, below detection limit (<0.016 mg/dl); CRP-II,  $\geq 0.016$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl; CRP-III,  $\geq 0.016$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl.



**Table S7** Additionally adjusted ORs with 95% CIs for hs-CRP levels and allergic outcomes estimated using generalized estimation equation models\*

Outcome	No. of observations	hs-CRP category <sup>†</sup>				
		I	II		III	
		Reference	OR (95% CI)	p value	OR (95% CI)	p value
Any sensitization	1932	1	0.93 (0.79, 1.09)	0.355	0.99 (0.79, 1.23)	0.900
Food sensitization	1932	1	1.08 (0.86, 1.35)	0.512	1.02 (0.75, 1.39)	0.878
Aeroallergen sensitization	1932	1	0.95 (0.80, 1.12)	0.515	1.03 (0.83, 1.28)	0.794
Asthma	1928	1	0.97 (0.65, 1.45)	0.894	0.78 (0.42, 1.43)	0.420
Eczema	1907	1	1.02 (0.69, 1.49)	0.934	0.80 (0.45, 1.44)	0.465
Allergic rhinitis	1930	1	1.07 (0.82, 1.40)	0.607	1.11 (0.77, 1.58)	0.577

Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; OR, odds ratio.

\*All models adjusted for time of follow-up, study area, sex, parental income, body mass index, and child's smoking at 15 years, study, atopic parents, and parental education level.

<sup>†</sup> CRP categories at 10 years old: CRP-I, below detection limit (<0.02 mg/dl); CRP-II,  $\geq 0.02$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl; CRP-III,  $\geq 0.02$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.02$  mg/dl. CRP categories at 15 years old: CRP-I, below detection limit (<0.016 mg/dl); CRP-II,  $\geq 0.016$  mg/dl and <75th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl; CRP-III,  $\geq 0.016$  mg/dl and  $\geq 75$ th sex-specific percentile of those with CRP  $\geq 0.016$  mg/dl.